Business Context and Reporting Period
Company: Aadi Bioscience, Inc. (Note: Request metadata listed "Whitehawk Therapeutics," but the filing text identifies the registrant as Aadi Bioscience, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: December 19, 2024
Reporting Period: Current event reporting for transactions executed on December 19, 2024.
The filing details a strategic restructuring involving the sale of a subsidiary, a new intellectual property license, and a private investment in public equity (PIPE) financing.
Key Financial Metrics and Transaction Values
- Subsidiary Sale (Stock Purchase): Aadi agreed to sell 100% of its subsidiary, Private Aadi, Inc., to KAKEN INVESTMENTS INC. for a purchase price of $100,000,000, subject to customary adjustments for cash, debt, and working capital.
- PIPE Financing: Aadi agreed to raise $100,000,000 through the sale of 21,592,000 shares of common stock at $2.40 per share and 20,076,500 pre-funded warrants at $2.3999 per share.
- License Agreement Upfront Payments: Aadi agreed to pay WuXi Biologics a non-refundable upfront payment of $6,000,000 immediately, plus an additional $38,000,000 within 90 days (extendable by 30 days).
- License Milestones: Potential future payments to WuXi Biologics include up to $265,000,000 in development milestones and $540,000,000 in commercial milestones, plus single-digit running royalties.
- Termination Fee: Aadi may be required to pay a termination fee of $3,500,000 to the Purchaser under specific circumstances (e.g., change of recommendation, superior proposal).
- Indemnification Cap: Aadi's indemnification obligations regarding representation breaches are capped at $5,000,000.
Note: The filing does not provide current revenue, profit, cash flow, or debt levels for the company as a whole, as this is a transactional report rather than a periodic financial statement.
Material Changes and Transaction Structure
- Spin-off/Sale of Assets: The company is divesting its subsidiary "Private Aadi" to KAKEN. This transaction is subject to stockholder approval and regulatory consents.
- Capital Structure Change: The PIPE Financing will significantly increase the number of outstanding shares. Certain directors and officers committed to purchasing $12,910,000 of the new securities.
- Strategic Partnership: Aadi is acquiring exclusive rights to three pre-clinical antibody drug conjugate (ADC) programs (targeting MUC16, PTK7, and SEZ6) from WuXi Biologics, leveraging DAC Biotechnology's linker payload technology.
- Board Composition: Baiteng Zhao, Ph.D., was appointed to the Board of Directors effective December 19, 2024. He is also a participant in the PIPE Financing ($3 million commitment).
Guidance, Outlook, Risks, and Contingencies
- Conditions Precedent: The Stock Purchase and PIPE Financing are contingent upon stockholder approval, regulatory approvals, and the absence of laws preventing the transaction. Closing is expected no later than five business days after stockholder approval for the PIPE.
- Timeline: The Purchase Agreement may be terminated if the closing does not occur by June 30, 2025 (extendable to September 30, 2025).
- Restrictive Covenants: Aadi is restricted from engaging in certain business activities for four years following the closing of the Stock Purchase. "No-shop" provisions limit Aadi's ability to solicit alternative proposals.
- Stockholder Support: Directors, officers, and significant stockholders controlling approximately 36% of outstanding shares have agreed to vote in favor of the transactions.
- Risks: Risks include failure to obtain stockholder approval, inability to meet development milestones for the WuXi Biologics license, and potential termination fees if the deal is abandoned for a superior proposal.
Investor Verification Checklist
- Verify the final purchase price of Private Aadi after customary adjustments for cash, debt, and working capital.
- Confirm the outcome of the special stockholder meeting required to approve the Stock Purchase and PIPE Financing.
- Review the definitive Proxy Statement for details on the "Superior Proposal" provisions and the specific terms of the termination fee.
- Monitor the execution of the second $38 million upfront payment to WuXi Biologics, as failure to pay will terminate the License Agreement.
- Check the dilution impact of the PIPE Financing (approx. 41.6 million new securities issued) on existing shareholders.